<DOC>
	<DOCNO>NCT00078585</DOCNO>
	<brief_summary>PROSTVAC-VF investigational cancer vaccine . The vaccine base theory immune system teach fight cancer direct immune system attack specific target find cancer cell . These target call Tumor Associated Antigens , TAA 's . This trial help determine vaccine help fight cancer . This multi-center , double-blind , randomize , empty vector-controlled trial design evaluate safety efficacy PROSTVAC-VF/TRICOM co-administered GM-CSF versus empty viral vector co-administered placebo treatment patient androgen-independent prostate cancer ( AIPC ) . All patient require sign inform consent prior performance on-study procedure . Patients screen eligibility within 14 day prior vaccine administration . Patients meet inclusion exclusion criterion centrally randomize study receive unique patient identification number blind treatment assignment . The ratio active treatment empty vector control ( placebo ) 2:1 .</brief_summary>
	<brief_title>PROSTVAC®-VF/TRICOM™ Vaccine Treatment Metastatic Prostate Cancer After Failing Hormone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Male patient &gt; 18 year age vaccinate smallpox ; Histological confirmation adenocarcinoma prostate evidence metastatic disease include either follow : Lymph node metastasis measurable CT and/or Bone metastasis evaluable bone scan ; Despite hormone therapy , evidence two consecutive increase PSA ( Prostate Specific Antigen ) ; Gleason Score 7 low initial diagnosis . Please note additional eligibility criterion must meet qualify . If qualify participate , study personnel explain trial detail answer question may . You decide whether wish participate . If qualify trial , study personnel explain reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>